ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

PRM Proteome Sciences Plc

4.15
0.64 (18.23%)
26 Apr 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Proteome Sciences Plc LSE:PRM London Ordinary Share GB0003104196 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.64 18.23% 4.15 3.50 4.80 - 423,867 16:35:28
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Biological Pds,ex Diagnstics 7.78M 1.33M 0.0045 7.80 10.36M
Proteome Sciences Plc is listed in the Biological Pds,ex Diagnstics sector of the London Stock Exchange with ticker PRM. The last closing price for Proteome Sciences was 3.51p. Over the last year, Proteome Sciences shares have traded in a share price range of 2.97p to 8.50p.

Proteome Sciences currently has 295,182,056 shares in issue. The market capitalisation of Proteome Sciences is £10.36 million. Proteome Sciences has a price to earnings ratio (PE ratio) of 7.80.

Proteome Sciences Share Discussion Threads

Showing 157326 to 157347 of 157525 messages
Chat Pages: 6301  6300  6299  6298  6297  6296  6295  6294  6293  6292  6291  6290  Older
DateSubjectAuthorDiscuss
12/3/2024
10:36
the leaker!
elpirata
11/3/2024
22:40
Imagine how Stephen Diggle must feel
canaletto
10/3/2024
22:38
....or two.

vbrs,

P. Snodgrass

jeffian
10/3/2024
20:35
Well I wish you a further generation .....
dominiccummings
10/3/2024
16:52
As I am now 89 I suspect I am only good for another 5 years, at best.

But I do remember discussing, in the 1980s, with a friend/cousin of the same age, whether or not we would make the millennium, and concluding the probability was around 50%. Which we both have. So who knows?

goatherd
09/3/2024
18:47
You got me!

But, actually, I really do not think that PRM is inevitably a hopeless cause.

I suppose I accept it may be. But hope dawns eternally in the human heart - - -
but then, if I am not human - - -

goatherd
09/3/2024
17:49
Yes. You are clearly an alien, here to promote hopeless causes.
dominiccummings
09/3/2024
17:41
Not really what I meant - and I don't see your logic (have you any, actually?).
goatherd
09/3/2024
17:32
You mean it is MORE often?
dominiccummings
09/3/2024
16:38
Have you enough data to back that "every 25 years".

I think not. :-)

goatherd
09/3/2024
13:37
Goatherd is like Dr Who. He regenerates himself every 25 years into a new Goatherd, then continues to cheer all PRM holders.
dominiccummings
09/3/2024
10:18
February 2024

Abstract and Figures

Single-cell proteomics is a powerful approach to precisely profile protein landscapes within individual cells toward a comprehensive understanding of proteomic functions and tissue and cellular states. The inherent challenges associated with limited starting material in single-cell analyses demands heightened analytical sensitivity. Just as advances in sample preparation maximize the amount of material that makes it from the cell to the mass spectrometer, we strive to maximize the number of ions that make it from ion source to the detector. In isobaric tagging experiments, limited reporter ion generation limits quantitative accuracy and precision. The combination of infrared photoactivation and ion parking circumvents the m/z dependence inherent in HCD, maximizing reporter generation and avoiding unintended degradation of TMT reporter molecules in a method we term activated ion-tandem mass tags (AI-TMT). The method was applied to single-cell human proteomes using 18-plex TMTpro, resulting in a 4-5-fold increase in reporter ion signal on average compared to conventional SPS-MS ³ approaches. AI-TMT enables faster duty cycles, higher throughput, and increased peptide identification and quantification. Comparative experiments showcase 4-5-fold lower injection times for AI-TMT, providing superior sensitivity without compromising accuracy. In all, AI-TMT enhances the sensitivity and dynamic range of proteomic experiments and is compatible with other techniques, including gas-phase fractionation and real-time searching, promising increased gains in the study of cellular heterogeneity and disease mechanisms.

pools2
09/3/2024
08:46
A heart attack if I remember correctly!
dominiccummings
09/3/2024
07:45
We need a crazy Tony around again,proper pump merchant,wonder what his reward was for all that guff.
peverill
08/3/2024
21:59
It's wonderful how with some of these dud shares one generation hands over to another, almost without mention with the new ethusiasts indistinguishable from the old.
When is the centenary?

dominiccummings
08/3/2024
19:52
Ah yes, TDM. MNT
There was also MDX where the Bell lost heavily, I recall
Anyone know what's happened to Mike Walters?
Seems his site has been discontinued

sandcrab2
08/3/2024
19:33
Where fgnoms, lamby, Saul and the rest of the old gang these days?
sandcrab2
08/3/2024
13:05
If someone wants to take us over they have to get the agreement of CJP and the Diggles first. I rather doubt they will.
goatherd
08/3/2024
12:26
We may have to go lower before going higher. We're in right location so it's a matter of time but tgat time might be 2 - 3 years, too long for some as there are other opportunities, each to their own but this will get taken over at some stage as its really too small to exist on its own 11 million market cap is probably away to high at this stage unfortunately
goggin
07/3/2024
18:40
The current CEO of PRM is proving herself to be uninspiring imo.
I’m still hopeful we may see 6p+ on the share price this year but without any update from PRM on the forward looking revenue outlook for 2024 it’s difficult to say.
We’ll get the FY results over next couple of months. The forward guidance will be critical for share price progress.
W41

wrighty41
05/3/2024
12:31
I would expect that long term ownership of this stock would confirm everything one needs to know regarding an avatars neurological health.
monte1
05/3/2024
12:04
MAPPING THE MIND: NEUROLOGICAL BIOMARKERS Published 20/09/2023

The Randox Health Signature programme incorporates testing of six key neurological biomarkers to provide an analysis of your neurological health.

GFAP
D-Dimer
GSTP1
IL-6
NDKA
PARK 7



All of above biomarkers are also in Randox Stroke Array licenced from Proteome Sciences

colinhy
Chat Pages: 6301  6300  6299  6298  6297  6296  6295  6294  6293  6292  6291  6290  Older

Your Recent History

Delayed Upgrade Clock